From Bench to Bedside: Immunotherapy for Prostate Cancer

被引:16
|
作者
Tse, Brian Wan-Chi [1 ]
Jovanovic, Lidija [1 ]
Nelson, Colleen Coyne [1 ]
de Souza, Paul [2 ]
Power, Carl Andrew [3 ]
Russell, Pamela Joan [1 ]
机构
[1] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia
[2] Univ Western Sydney, Sydney Sch Med, Ingham Inst Appl Med Res, Sydney, NSW 2170, Australia
[3] Univ New S Wales, Lowy Canc Res Ctr, Biol Resources Imaging Lab, Sydney, NSW 2052, Australia
关键词
ALLOGENEIC CELLULAR IMMUNOTHERAPY; REGULATORY T-CELLS; PHASE-I TRIAL; SIPULEUCEL-T; DOSE-ESCALATION; GM-CSF; ADAPTIVE IMMUNITY; CTLA-4; BLOCKADE; DOUBLE-BLIND; OPEN-LABEL;
D O I
10.1155/2014/981434
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, immunotherapy has also emerged as an option for the treatment of this disease following the approval of sipuleucel-T by the FDA in 2010. Immunotherapy is a rational approach for prostate cancer based on a body of evidence suggesting these cancers are inherently immunogenic and, most importantly, that immunological interventions can induce protective antitumour responses. Various forms of immunotherapy are currently being explored clinically, with the most common being cancer vaccines (dendritic-cell, viral, and whole tumour cell-based) and immune checkpoint inhibition. This review will discuss recent clinical developments of immune-based therapies for prostate cancer that have reached the phase III clinical trial stage. A perspective of how immunotherapy could be best employed within current treatment regimes to achieve most clinical benefits is also provided.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Cancer Therapy from Bench to Bedside
    Oh, William K.
    Burakoff, Steven J.
    MOUNT SINAI JOURNAL OF MEDICINE, 2010, 77 (06): : 571 - 572
  • [42] Cancer research - From bench to bedside
    Izraeli, S
    Witz, I
    Micksche, M
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (09): : 746 - 748
  • [43] Externally-Controlled Systems for Immunotherapy: From Bench to Bedside
    Tristan-Manzano, Maria
    Justicia-Lirio, Pedro
    Maldonado-Perez, Noelia
    Cortijo-Gutierrez, Marina
    Benabdellah, Karim
    Martin, Francisco
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [44] Tumor immunotherapy with bispecific antibodies: From bench- to bedside
    Jung, G
    GrosseHovest, L
    Brandl, M
    Pfosser, A
    Wilmanns, W
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 89 - 89
  • [45] TIGIT: a novel immunotherapy target moving from bench to bedside
    Benjamin L. Solomon
    Ignacio Garrido-Laguna
    Cancer Immunology, Immunotherapy, 2018, 67 : 1659 - 1667
  • [46] Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers
    Acebes-Fernandez, Vanessa
    Landeira-Vinuela, Alicia
    Juanes-Velasco, Pablo
    Hernandez, Angela-Patricia
    Otazo-Perez, Andrea
    Manzano-Roman, Raul
    Gongora, Rafael
    Fuentes, Manuel
    NANOMATERIALS, 2020, 10 (07) : 1 - 72
  • [47] TIGIT: a novel immunotherapy target moving from bench to bedside
    Solomon, Benjamin L.
    Garrido-Laguna, Ignacio
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (11) : 1659 - 1667
  • [48] Managing the impact of immunogenicity in an era of immunotherapy: from bench to bedside
    Bray-French, Katharine
    Hartman, Katharina
    Steiner, Guido
    Marban-Doran, CSeline
    Bessa, Juliana
    Campbell, Neil
    Martin-Facklam, Meret
    Stubenrauch, Kay-Gunnar
    Solier, Corinne
    Singer, Thomas
    Ducret, Axel
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (07) : 2575 - 2584
  • [49] Targeting gamma delta T cells for cancer immunotherapy: bench to bedside
    Gogoi, Dimpu
    Chiplunkar, Shubhada V.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2013, 138 : 755 - 761
  • [50] Normalizing the Tumor Microenvironment to Improve Cancer Immunotherapy: Bench to Bedside and Back
    Jain, Rakesh K.
    CANCER SCIENCE, 2023, 114 : 1591 - 1591